Dupilumab for the treatment of atopic dermatitis of the elderly: a real-life 52-week experience

Figures & data

Table 1. Demographic and clinical characteristics of the patients.

Age, years
Mean ± SD	75,97 ± 6,49
Range	65-89
Average age at symptom onset, years ± SD	68,87 ± 13,91
Male sex, n (%)	21 (52,5%)
Atopic dermatitis onset, n (%)
Onset < 65 years	10 (25%)
Onset ≥ 65 years	30 (75%)
Atopic comorbidities, n (%)
Rhinitis	8 (20%)
Asthma	4 (10%)
Conjunctivitis	5 (12,5%)
Food allergy	5 (12,5%)
Positive patch test	10 (25%)
Drug allergy	6 (15%)
Atopic dermatitis phenotype, n (%)
Flexural dermatitis	19 (47,5%)
Generalized eczema with an inflammatory pattern	4 (10%)
Generalized eczema with an inflammatory pattern	4 (10%)
Prurigo Nodularis	6 (15%)
Nummular eczema	7 (17,5%)
Previous exposure to Cyclosporin, n (%)	8 (20%)
New onset after COVID-19 vaccine, n (%)	5 (12,5%)

Figure 1. Percentages of patients that reached EASI 75, EASI 90, EASI 100, Validated Investigator Global Assessment scale for Atopic Dermatitis (vIGA-AD) score 0 or 1 (left); percentages of mean delta EASI variation from baseline (top right); percentages of patients that reached a difference of pruritus-NRS of four points from baseline (bottom right).

Data availability statement

Data available on request from the authors.